The 340B Drug Pricing Program at a Crossroads
This Viewpoint presents the history of the Health Resources & Services Administration (HRSA) 340B Drug Pricing Program and 340B Rebate Model Pilot Program, summarizes their controversies and limitations, and calls for action by Congress and HRSA to address these issues and strengthen support for safety-net hospitals and clinics.
Authors
- Ameet Sarpatwari (ORCID: https://orcid.org/0000-0001-5043-6206)
- Ryan P. Knox
Institutions
- DePaul University (US)
- Harvard University (US)
- Harvard Pilgrim Health Care (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-05-18
- DOI
- https://doi.org/10.1001/jama.2026.6812
- Primary Topic
- Medication Adherence and Compliance
- Type
- article
- Field-Weighted Citation Impact
- 0.00